In systemic lysozyme amyloidosis, for example, the deposits can grow to kilogram quantities in the liver [3,4], whereas in neurodegenerative diseases, where the quantity of aggregates can be almost undetectable in some cases [5], there is no clear correlation between the amount of amyloid deposition and the clinical severity of the disease. Here, LYZ is linked to amyloidosis.